ApoE2 Allele, Down's Syndrome, and Dementiaa
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
All individuals with Down's syndrome (trisomy 21‐DS) develop the pathogenic hallmarks of Alzheimer's disease in old age (+40 years).1‐4 The extent of pathology is variable, but it has been shown that the amount of β‐amyloid pathology is variable and related to age and the degree of dementia.3 Thus, in DS, growing old is associated with a progressive pathological process which results in cognitive decline. However, neuropsychological studies of older DS subjects have identified a clinical dementia in only a proportion of cases.1‐4 These contradictory observations could be reconciled if some factor existed which modulated the rate and amount of β‐amyloid pathology. Recent studies demonstrate an association between the apolipoprotein E4 (ApoE4) allele and the earlier age of onset in both sporadic 8‐9 and familial 10 AD. Increased amounts of βamyloid pathology can also be related to the E4 allele. However, at present there are no data documenting the effects of ApoE genotype on the expression or degree of clinical symptoms of the disease. We have examined the ApoE genotype in a cohort of clinically evaluated elderly patients with DS in order to examine the effects of ApoE genotype on the clinical symptoms of dementia. We report here that, despite the presence of an active disease process, the ApoE E2 allele is associated with longevity and preservation of cognitive functioning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic associations with human longevity at the APOE and ACE loci
Schächter, F., Faure-Delanef, L., Guénot, F., Rouger, H., Froguel, P., Lesueur-Ginot, L., & Cohen, D. (1994) · Nature Genetics · doi:10.1038/ng0194-29 · Cited by 1,095
Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913
Cited by
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
“Similar observations have been made in subjects with Down syndrome (OMIM#190685), who, due to trisomy of chromosome 21, carry three copies of APP and develop early-onset AD pathology (Coppus et al., 2008; Royston et al., 1996).”
The four ages of Down syndrome
Bittles, A. H., Bower, C., Hussain, R., & Glasson, E. J. (2007) · The European Journal of Public Health · doi:10.1093/eurpub/ckl103 · Cited by 492
Atypical aging in down syndrome
Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 260
APOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome
Jones, E. L., Mok, K., Hanney, M., Harold, D., Sims, R., Williams, J., & Ballard, C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.018 · Cited by 47
Metadata
- Authors
- ROYSTON, M. C., MANN, D., PICKERING‐BROWN, S., OWEN, F., PERRY, R., RAGBHAVAN, R., KHIN‐NU, C., TYNER, S., DAY, K., CROOK, R., HARDY, J., & ROBERTS, G. W.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 1996-01
- Volume
- 777
- Issue
- 1
- Pages
- 255-259
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1980769320
- Cited by
- 21
- References
- 2
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ApoE2 Allele, Down's Syndrome, and Dementiaa. https://app.cochat.ai/papers/10.1111/j.1749-6632.1996.tb34428.x
- The paper
- ROYSTON, M. C., MANN, D., PICKERING‐BROWN, S., OWEN, F., PERRY, R., RAGBHAVAN, R., KHIN‐NU, C., TYNER, S., DAY, K., CROOK, R., HARDY, J., & ROBERTS, G. W. (1996). ApoE2 Allele, Down's Syndrome, and Dementiaa. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1996.tb34428.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.